Effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 383, Issue 6, 2011, Pages 585-591

  Pan, Si Yuan ^a   Dong, Hang ^b   Guo, Bao Feng ^a   Zhang, Yi ^a   Yu, Zhi Ling ^b   Fong, Wang Fun ^b   Han, Yi Fan ^c   Ko, Kam Ming ^d  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Fatty liver; Fenofibrate; Hepatomegaly; Hypertriglyceridemia; Schisandrin B; Total cholesterol

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FENOFIBRATE; SCHIZANDRIN B; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; DOSE RESPONSE; DRUG ACTIVITY; ENZYME ACTIVITY; LIPID LIVER LEVEL; LIVER FUNCTION; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PREMEDICATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CHOLESTEROL; CYCLOOCTANES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FENOFIBRATE; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LIGNANS; LIVER; MALE; MICE; MICE, INBRED ICR; POLYCYCLIC COMPOUNDS; SCHISANDRA; TRIGLYCERIDES;

EID: 79959373980     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0634-x     Document Type: Article

References (24)

1. P Alagona Jr 2010 Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia Vasc Health Risk Manag 6 351 362 20531954 10.2147/VHRM.S6714 1:CAS:528:DC%2BC3cXms1Wnu7k%3D
2. Y Andersson Z Majd AM Lefebvre G Martin AV Sechkin V Kosykh JC Fruchart J Najib B Staels 1999 Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation Arterioscler Thromb Vasc Biol 19 115 121 9888873 1:CAS:528: DyaK1MXms1Kkug%3D%3D (Pubitemid 29031919)
3. HP Cotrim ER Parise CP Oliveira N Leite A Martinelli J Galizzi C Silva Rde A Mattos L Pereira W Amorim C Ivantes F Souza M Costa L Maia M Pessoa F Oliveira 2011 Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile Ann Hepatol 10 33 37 21301007
4. K Gopal K Kumar R Nandini P Jahan MJ Kumar 2010 High fat diet containing cholesterol induce aortic aneurysm through recruitment and proliferation of circulating agranulocytes in apoE knock out mice model J Thromb Thrombolysis 30 154 163 20177736 10.1007/s11239-010-0446-8 1:CAS:528:DC%2BC3cXpt12mtrY%3D
5. SP Ip MK Poon SS Wu CT Che KH Ng YC Kong KM Ko 1995 Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity Planta Med 61 398 401 7480197 10.1055/s-2006-958123 1:CAS:528:DyaK2MXpt1Ogs74%3D
6. Ko RKM, Mak DHF (2004) Schisandrin B and other dibenzocyclooctadiene ligands. In: Lester P, Ong C, Halliwell B (eds) Herbal and traditional medicine. Molecular Aspects of Health. Marcel Dekker, New York, pp 289-314
7. SH Lee IM Chung YS Cha Y Park 2010 Millet consumption decreased serum concentration of triglyceride and C-reactive protein but not oxidative status in hyperlipidemic rats Nutr Res 30 290 296 20534332 10.1016/j.nutres.2010.04.007 1:CAS:528:DC%2BC3cXmslWgsrg%3D
8. YC Lin HM Lo JD Chen 2005 Sonographic fatty liver, overweight and ischemic heart disease World J Gastroenterol 11 4838 4842 16097054
9. MC Lin SH Kao PJ Chung KC Chan MY Yang CJ Wang 2009 Improvement for high fat diet-induced hepatic injuries and oxidative stress by flavonoid-enriched extract from Nelumbo nucifera leaf J Agric Food Chem 57 5925 5932 19499892 10.1021/jf901058a 1:CAS:528:DC%2BD1MXmvVelsL4%3D
10. ZJ Lin B Zhang XQ Liu HL Yang 2009 Abdominal fat accumulation with hyperuricemia and hypercholesterolemia quail model induced by high fat diet Chin Med Sci J 24 191 194 19848323 10.1016/S1001-9294(09)60088-2 1:CAS:528:DC%2BD1MXhtlyns7vJ
11. Y Miura M Hosono C Oyamada H Odai S Oikawa K Kondo 2005 Dietary isohumulones, the bitter components of beer, raise plasma HDL-cholesterol levels and reduce liver cholesterol and triacylglycerol contents similar to PPARalpha activations in C57BL/6 mice Br J Nutr 93 559 567 15946420 10.1079/BJN20041384 1:CAS:528:DC%2BD2MXls1Squ7w%3D
12. M Neumeier J Weigert A Schäffler TS Weiss C Schmidl R Büttner C Bollheimer C Aslanidis J Schölmerich C Buechler 2006 Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro Biochem Biophys Res Commun 350 731 735 17022944 10.1016/j.bbrc.2006.09.101 1:CAS:528:DC%2BD28XhtVyisbnK (Pubitemid 44547907)
13. SY Pan YF Han 2004 Comparison of the inhibitory efficacy of four belladonna drugs on gastrointestinal movement and cognitive function in food-deprived mice Pharmacology 72 177 183 15452366 10.1159/000080102 1:CAS:528:DC%2BD2cXnvFanuro%3D (Pubitemid 39370246)
14. SY Pan H Dong YF Han WY Li XY Zhao KM Ko 2006 A novel experimental model of acute hypertriglyceridemia induced by schisandrin B Eur J Pharmacol 537 200 204 16624278 10.1016/j.ejphar.2006.03.001 1:CAS:528:DC%2BD28XktVegt7w%3D
15. SY Pan R Yang YF Han H Dong XD Feng N Li W Geng KM Ko 2006 High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: animal models of acute hypertriglyceridemia Acta Pharmacol Sin 27 673 678 16723084 10.1111/j.1745-7254.2006.00332.x 1:CAS:528:DC%2BD28XmtFeru7g%3D (Pubitemid 43943914)
16. SY Pan R Yang H Dong ZL Yu KM Ko 2006 Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice Eur J Pharmacol 552 170 175 17046746 10.1016/j.ejphar.2006.09.011 1:CAS:528:DC%2BD28XhtFKmurrJ (Pubitemid 44648081)
17. H Ren B Vallanat HM Brown-Borg R Currie JC Corton 2010 Regulation of proteome maintenance gene expression by activators of peroxisome proliferator-activated receptor α PPAR Res 10.1155/2010/727194 21318169
18. W Rosamond K Flegal K Furie A Go K Greenlund N Haase SM Hailpern M Ho V Howard B Kissela S Kittner D Lloyd-Jones M McDermott J Meigs C Moy G Nichol C O'Donnell V Roger P Sorlie J Steinberger T Thom M Wilson Y Hong American Heart Association Statistics Committee and Stroke Statistics Subcommittee 2008 Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 117 e25 146 18086926 10.1161/CIRCULATIONAHA.107.187998
19. R Thibaut S Schnell C Porte 2006 The interference of pharmaceuticals with endogenous and xenobiotic metabolizing enzymes in carp liver: an in-vitro study Environ Sci Technol 40 5154 5160 16955921 10.1021/es0607483 1:CAS:528:DC%2BD28XmsFCmtbw%3D (Pubitemid 44257486)
20. H Tilg A Kaser 2005 Treatment strategies in nonalcoholic fatty liver disease Nat Clin Pract Gastroenterol Hepatol 2 148 155 16265156 10.1038/ncpgasthep0116 1:CAS:528:DC%2BD2MXjtFyjtL4%3D (Pubitemid 40812514)
21. JW van der Hoorn JW Jukema LM Havekes E Lundholm G Camejo PC Rensen HM Princen 2009 The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice Br J Pharmacol 156 1067 1075 19220285 10.1111/j.1476-5381.2008.00109.x
22. AS Wierzbicki 2010 Fibrates: no ACCORD on their use in the treatment of dyslipidaemia Curr Opin Lipidol 21 352 358 20625256 10.1097/MOL.0b013e32833c1e74 1:CAS:528:DC%2BC3cXovV2ltro%3D
23. PW Yoon X Tong SM Schmidt D Matson-Koffman 2011 Clinical preventive services for patients at risk for cardiovascular disease, national ambulatory medical care survey, 2005-2006 Prev Chronic Dis 8 A43 21324257
24. S Zadelaar R Kleemann L Verschuren J De Vries-Van der Weij J van der Hoorn HM Princen T Kooistra 2007 Mouse models for atherosclerosis and pharmaceutical modifiers Arterioscler Thromb Vasc Biol 27 1706 1721 17541027 10.1161/ATVBAHA.107.142570 1:CAS:528:DC%2BD2sXns1amsr4%3D (Pubitemid 47207165)